CBX - China Biotech XYZ

Hansoh conducted a new clinical study to evaluate the efficacy of anti-B7H4 ADC in combination with anti-PD-L1 or anti-VEGF mAbs for treating solid tumors. This marks the 3rd clinical trial for HS-20089 in China. HS-20089 is a novel B7-H4 targeted ADC with a TOPOi payload (DAR=6) , developed by Hansoh and licensed to GSK with an $85 million upfront payment. Factors controlling B7-H4 and B7-H4 receptor expression The clinical study This study contains four combination therapy cohorts, each consisting of a dose exploration part and a dose expansion part. The combination includes Adebrelimab, an anti-PD-L1 monoclonal antibody, either with or without platinum, or Bevacizumab with or without platinum. Adebrelimab was an anti-PD-L1 monoclonal antibody discovered and launched by Hengrui in China as their second anti-PD-(L)1 therapy. The clinical trial identified as NCT06336707 is expected to enroll a total of 1,048 participants, while the trial registered in China (CTR20241023) showed an e